ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Advanced Search

Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3

C. Schardt, R. Yau, A. Burgos, C. Tunwar

Pharmacy, CHI St. Luke's Health Baylor St. Luke's Medical Center, Houston, TX

Meeting: 2020 American Transplant Congress

Abstract number: D-002

Keywords: Immunosuppression, Interleukin-2 receptor, Rejection, Simulect

Session Information

Date: Saturday, May 30, 2020

Session Name: Poster Session D: Kidney Immunosuppression: Induction Therapy

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

Related Abstracts
  • Basiliximab Induction With Delayed Tacrolimus Initiation up to 14 Days Post Liver Transplantation Maintains Excellent Clinical Outcomes While Preserving Renal Function
  • Comparison of Anti-Thymocyte Globulin and Alemtuzumab as Induction Therapy in Older Kidney Transplant Recipients

*Purpose: Current dosing recommendations for the administration of basiliximab on post-operative days (POD) 0 and 4 stem from two phase 3 renal transplant studies. Limited studies have explored alternative dosing strategies and found no difference in the incidence of graft loss 12 months post-transplant. The purpose of this study is to compare outcomes of basiliximab for induction therapy on POD 0 and 4 versus POD 0 and 3 in kidney transplant recipients. The results from this study may confirm this alternative dosing strategy as equally effective to conventional dosing which may lead to a shorter length of stay post kidney transplant.

*Methods: A single center retrospective, observational chart review was performed in kidney transplant recipients who received basiliximab induction therapy between January 2017 and May 2019. The primary endpoint was to compare the incidence of biopsy-proven rejection (BPR) rates at 1, 3, and 6 months post-transplant. Secondary endpoints included six month graft and patient survival, mean tacrolimus levels, and length of stay. Patients were excluded if they did not have documentation of basiliximab administration, were lost to follow-up, or had medication non-compliance.

*Results: A total of 91 patients were included in this study: 45 received basiliximab on POD 0 and 3, 46 received basiliximab on POD 0 and 4. There was no significant difference in BPR at 1 month (9 v 7%, p=0.713), 3 months (13 v 17%, p=0.773), and 6 months (16 v 20%, p=0.784) between patients receiving basiliximab on POD 0 and 3 versus POD 0 and 4. There was no difference in mean tacrolimus levels at 6 months between the two groups (9.2 ± 1.2 v 9.6 ± 2.0, p=0.327). Overall graft and patient survival was similar between groups with one death in the POD 0 and 3 group due to an unknown cause several days after initial discharge. Length of stay was not statistically significant between the groups, but the trend was shorter for the POD 0 and 3 group compared to POD 0 and 4 (5.2 ± 2.1 v 5.9 ± 2.1 days, p=0.051).

*Conclusions: In this retrospective chart review, we found that BPR rates were similar between the two groups up to 6 months after kidney transplantation as well as graft and patient survival. Length of stay was numerically shorter with basiliximab administration POD 0 and 3 compared to POD 0 and 4. From our institutional results, administering basiliximab on POD 0 and 3 is as efficacious and can lead to shorter length of stay in our kidney transplant patients.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Schardt C, Yau R, Burgos A, Tunwar C. Comparison of Basiliximab for Induction Therapy in Kidney Transplant Recipients on Post-Operative Days 0 and 4 versus Post-Operative Days 0 and 3 [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/comparison-of-basiliximab-for-induction-therapy-in-kidney-transplant-recipients-on-post-operative-days-0-and-4-versus-post-operative-days-0-and-3/. Accessed March 4, 2021.

« Back to 2020 American Transplant Congress

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Subtherapeutic Low Tacrolimus Trough Levels (≤3.5 Ng /ml) Are A Risk Factor For Acute Rejection And Creatinine Doubling.
  • Penis Transplantation: First U.S. Experience.
  • A Decade of Donor-Derived Disease: A Report of the OPTN Ad Hoc Disease Transmission Advisory Committee (DTAC).
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Penis Transplantation: First U.S. Experience.
  • Is There a Difference Between DCD and DBD Kidney Transplantation with Similar KDPI?
  • Low GFR after Kidney Donation Is Not Chronic Kidney Disease
  • Evidence of a Clinically Significant Drug-Drug Interaction between Cannabidiol and Tacrolimus: A Case Report
  • Kidney Dialysis after Heart Transplantation: The Short and Long Term Outcomes

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2021 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy

loading Cancel
Post was not sent - check your email addresses!
Email check failed, please try again
Sorry, your blog cannot share posts by email.
This site uses cookies: Find out more.